Plus Therapeutics (PSTV) News Today $1.52 +0.05 (+3.40%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.38 -0.15 (-9.54%) As of 03/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timelineMarch 28 at 2:42 AM | msn.comPlus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call TranscriptMarch 27 at 8:04 PM | seekingalpha.comPlus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 27 at 4:05 PM | globenewswire.comWhy Plus Therapeutics Is Rising In Pre-market?March 22, 2025 | nasdaq.comPlus Therapeutics announces FDA conditionally accepted name REYOBIQMarch 21, 2025 | markets.businessinsider.comWhy Plus Therapeutics Inc. (PSTV) Surged On Thursday?March 21, 2025 | msn.comPlus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug CandidateMarch 20, 2025 | globenewswire.comPlus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025March 19, 2025 | globenewswire.comD. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)March 19, 2025 | americanbankingnews.comD. Boral Capital Initiates Coverage of Plus Therapeutics (PSTV) with Buy RecommendationMarch 18, 2025 | msn.comPlus Therapeutics initiated with a Buy at D. Boral CapitalMarch 17, 2025 | markets.businessinsider.comD. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. in Connection with its up to $15.0 Million Private PlacementMarch 11, 2025 | finanznachrichten.dePlus regains compliance with Nasdaq minimum stockholders’ equity requirementMarch 10, 2025 | markets.businessinsider.comPlus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity RequirementMarch 10, 2025 | finance.yahoo.comPlus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementMarch 10, 2025 | globenewswire.comPlus Therapeutics Stock Price, Quotes and ForecastsMarch 7, 2025 | benzinga.comPlus Therapeutics announces publication of results on 186Re ObisbemedaMarch 7, 2025 | markets.businessinsider.comPlus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in GlioblastomaMarch 7, 2025 | globenewswire.comPlus Therapeutics granted Orphan Drug Designation for Rhenium ObisbemedaMarch 6, 2025 | markets.businessinsider.comPlus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatmentMarch 6, 2025 | msn.comPlus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung CancerMarch 6, 2025 | globenewswire.comPlus Therapeutics Announces New Employment Inducement GrantsMarch 5, 2025 | globenewswire.comPlus Therapeutics sees $15M in gross proceeds from private placementMarch 4, 2025 | markets.businessinsider.comPlus Therapeutics Secures Private Placement of Approximately $15 Million in Gross ProceedsMarch 4, 2025 | globenewswire.comPlus Therapeutics granted orphan designation for lung cancer treatmentMarch 1, 2025 | markets.businessinsider.comPlus Therapeutics advances Rhenium ObisbemedaFebruary 27, 2025 | markets.businessinsider.comPlus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal MetastasesFebruary 26, 2025 | globenewswire.comPlus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics SubsidiaryFebruary 24, 2025 | markets.businessinsider.comPlus Therapeutics appoints Russell Bradley as president, CNSideFebruary 24, 2025 | markets.businessinsider.comPlus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics SubsidiaryFebruary 24, 2025 | globenewswire.comPlus Therapeutics apoints Michael Rosol as Chief Development OfficerFebruary 20, 2025 | markets.businessinsider.comPlus Therapeutics Appoints Dr. Michael Rosol as Chief Development OfficerFebruary 20, 2025 | globenewswire.comPlus Therapeutics secures $5.7M financingFebruary 19, 2025 | markets.businessinsider.comPlus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases ProgramFebruary 18, 2025 | globenewswire.comPlus Therapeutics presented data on ReSPECT-LM Phase 1 trialDecember 18, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumDecember 17, 2024 | globenewswire.comPlus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumDecember 4, 2024 | globenewswire.comPlus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope SupplyDecember 3, 2024 | globenewswire.comPlus Therapeutics presents updated progress from its ReSPECT-LM Phase 1 trialNovember 27, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Diagnostic Innovations Drive Buy Rating for Plus TherapeuticsNovember 27, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual ConferenceNovember 25, 2024 | globenewswire.comPlus Therapeutics to present FORESEE clinical trial summaryNovember 23, 2024 | markets.businessinsider.comPlus Therapeutics subsidiary to present data on CNSide CSF Assay PlatformNovember 22, 2024 | markets.businessinsider.comPlus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal MetastasesNovember 22, 2024 | globenewswire.comPlus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal MetastasesNovember 21, 2024 | globenewswire.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2024 Earnings Call TranscriptNovember 18, 2024 | msn.comPositive Outlook for Plus Therapeutics: Strong Financial Support and Clinical Advancements Justify Buy RatingNovember 17, 2024 | markets.businessinsider.comPlus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | seekingalpha.comPlus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 16, 2024 | finanznachrichten.dePlus Therapeutics: Promising Growth and Stability Backed by Financial Strength and Clinical InnovationsNovember 15, 2024 | markets.businessinsider.com Remove Ads Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTV Media Mentions By Week PSTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼0.530.79▲Average Medical News Sentiment PSTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼92▲PSTV Articles Average Week Remove Ads Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SurgePays News Today Retractable Technologies News Today Vivos Therapeutics News Today NEXGEL News Today Beyond Air News Today ReWalk Robotics News Today Nephros News Today Allurion Technologies News Today IRIDEX News Today NeurAxis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
